HIMS jumps 7% on peptide tailwind — but Citi sees 17% downside from here

🌐 Investing.com (Cyprus) —
HIMS jumps 7% on peptide tailwind — but Citi sees 17% downside from here

AI Summary

Hims & Hers Health shares rose 7% amid favorable momentum around peptides, while Citi sees 17% downside from the current price. The headline does not specify the underlying catalyst or Citi's valuation rationale.

Markets Health Hims & Hers Health HIMS peptides Citi share price analyst outlook

Read original source →